Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28715201 | 0.91 | IGF1R (0.52) | CYP1A2CYP2A6TAAR1KCNH2IDO1 | |
| SCHEMBL12505677 | 0.91 | CYP1A2 (0.48) | CYP1A2CYP2A6TAAR1KCNH2IDO1 | |
| SCHEMBL3533774 | 0.85 | IDO1 (0.44) | CYP1A2CYP2A6TAAR1IDO1DAO | |
| SCHEMBL143961 | 0.84 | CYP1A2 (0.68) | CYP1A2CYP2A6TAAR1KCNH2IDO1 | |
| SCHEMBL6576818 | 0.84 | GFER (0.40) | CYP2A6TAAR1KCNH2ALOX15TDP1 | |
| SCHEMBL11288839 | 0.84 | CYP1A2 (0.68) | CYP1A2CYP2A6TAAR1KCNH2IDO1 | |
| SCHEMBL27629737 | 0.80 | LPL (0.46) | ALDH1A1GPR84L3MBTL1 | |
| SCHEMBL28389357 | 0.80 | TAAR1 (0.52) | CYP2A6TAAR1TDP1ALDH1A1GPR84 | |
| SCHEMBL4573326 | 0.79 | CHRM2 (0.53) | IDO1ALOX15MEN1ALDH1A1KMT2A | |
| SCHEMBL28468636 | 0.78 | IDO1 (0.38) | CYP1A2CYP2A6TAAR1IDO1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3201205-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-10640520-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| EP-3201205-A1 | BORONIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-12-08 | — | — | US | disclosed |
| US-9453007-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2016050355-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9173887-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| US-5290934-A | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0354871-B1 | Corrosion inhibition | CIBA GEIGY AG (CH) | 1993-11-24 | — | — | EP | disclosed |
| US-5176850-A | Corrosion Inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-01-05 | — | — | US | disclosed |
| US-5013482-A | Ether acids | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0407955-A1 | New hetrazepines acting as PAF antagonists, process for their production and their use as drugs | BOEHRINGER INGELHEIM KG (DE) | 1991-01-16 | — | — | EP | disclosed |
| EP-0354871-A2 | Corrosion inhibition | CIBA-GEIGY AG (CH) | 1990-02-14 | — | — | EP | disclosed |
| US-4895987-A | Phosphonite-and phosphonite-promoted ruthenium - cobalt catalysts for the dealkoxyhydroxymethylation of acetals to form glycol ethers | SUN REFINING AND MARKETING COMPANY (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0312659-A1 | Phosphonite-and phosphinite-promoted ruthenium - cobalt catalysts for the dealkoxyhydroxymethylation of acetals to form glycol ethers | Sun Refining and Marketing Company (US) | 1989-04-26 | — | — | EP | disclosed |
| US-3946081-A | OXIDATION CATALYSTS, GROUP V, VI, OR VII OXIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179231-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | CYP1A2 3721/4885CYP2A6 1313/4885TAAR1 3696/4885 |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | CYP1A2 1669/4885CYP2A6 1011/4885TAAR1 4543/4885 |
| US-10640520-B2 | Boronic acid derivatives | BCL9, BCL9L, BCL6 | CYP1A2 3721/4885CYP2A6 1313/4885TAAR1 3696/4885 |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | CYP1A2 1669/4885CYP2A6 1011/4885TAAR1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.